rTMS — Repetitive Transcranial Magnetic Stimulation
Evidence-supportedA/BgradePlausibility · Plausible / established (narrow)Electromagnetic Field
Evidence-supported · Evidence-supported
Cleared psychiatric indications: treatment-resistant major depressive disorder, OCD, and later-cleared expansions (anxious depression, adolescent depression).
Off-label · Not established (ungraded)
Longevity, anti-aging, and general cognitive-enhancement framing beyond cleared indications.
rTMS is a cleared, trial-backed focal magnetic neurostimulation in which a pulsed coil field is delivered to targeted cortex to treat treatment-resistant depression and obsessive-compulsive disorder. It is the mechanism-grounded magnetic counterpart to coil-based 'field' devices, but is categorically distinct from sub-threshold PEMF: rTMS pulses are supra-threshold and depolarize neurons, whereas PEMF acts at sub-threshold tissue-level fields. The depression and OCD indications are supported by multisite randomized trials and meta-analyses (lead RCT: O'Reardon 2007). Longevity, anti-aging, and general cognitive-enhancement framings are not established and fall outside any cleared indication.
Origin & lineage
rTMS descends from Anthony Barker's 1985 demonstration of non-invasive transcranial magnetic stimulation at Sheffield, maturing into a clinical neurostimulation modality with Neuronetics' NeuroStar receiving the first FDA clearance for major depressive disorder in 2008.
Claimed mechanism
A rapidly changing focal magnetic field induced by a coil over the scalp drives supra-threshold depolarization of underlying cortical neurons, acutely and (with repetition) durably modulating excitability across connected networks. Dose is defined by stimulus intensity (expressed as a percentage of the individual's resting motor threshold), pulse frequency, train pattern, and the number of sessions in a course.
Plausibility
Plausible / established (narrow) — mechanism is direct neuronal depolarization, with established efficacy confined to the cleared psychiatric indications.
Evidence — grade A/B
Grade A applies to the cleared psychiatric indications (treatment-resistant MDD, OCD), supported by multisite randomized controlled trials and meta-analyses. Grade B applies to newer or broader indications where evidence is thinner or still accruing. The device is therefore held at A/B rather than a flat A.
Cross-reference
rTMS is NOT a PEMF duplicate — it uses supra-threshold pulses that depolarize neurons, where PEMF works sub-threshold at the tissue level — and it sits as a cleared, trial-backed magnetic sibling to TTFields among genuine field therapies, in contrast to the unproven 'frequency'-coil tradition (Lakhovsky/Mishin/Rife).
Market
Makers: Class examples include Neuronetics (NeuroStar), MagVenture, and Brainsway (deep TMS); these are representative of the device class, not endorsements. Models: NeuroStar Advanced Therapy System, MagVenture TMS Therapy, Brainsway Deep TMS (H-coil) — examples of the cleared focal/deep TMS class. Price: Typically delivered as a multi-week clinical course of daily sessions; course pricing is on the order of thousands of US dollars and varies by indication, protocol, and coverage. Not specified in source.
Kernel — keep vs set aside
Keep — real substrate
Keep the cleared use: focal pulsed magnetic neurostimulation for treatment-resistant depression and OCD, backed by multisite randomized controlled trials and meta-analyses.
Set aside — claim
Set aside any longevity, anti-aging, or general cognitive-enhancement framing presented as established benefit beyond the cleared psychiatric indications; such claims are not supported.
Regulatory status by jurisdiction
Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA
FDA-cleared via the 510(k) pathway (NeuroStar lineage, Neuronetics): first MDD clearance 2008, OCD clearance 2018, with later expansions including anxious depression and adolescent depression. openFDA records the NeuroStar Transcranial Magnetic Stimulator clearance lineage, e.g. K220127 (decision 2022-07-15), product code OBP, regulation 882.5805, device class 2. Clearance is a market-access fact, not a measure of efficacy.
FDA clearance is cited as a market-access fact, with the NeuroStar (Neuronetics) Transcranial Magnetic Stimulator clearance lineage confirmed via the openFDA 510(k) database (including K220127). The efficacy anchor is the pivotal multisite RCT O'Reardon 2007 (Biol Psychiatry), evidencing benefit in treatment-resistant major depression.